Menu Search
Equities

Lumibird SA

LBIRD:PAR

Lumibird SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)7.30
  • Today's Change0.000 / 0.00%
  • Shares traded6.67k
  • 1 Year change-44.27%
  • Beta1.3393
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Lumibird SA had net income fall -37.24% from 11.35m to 7.13m despite a 6.60% increase in revenues from 190.96m to 203.56m.
Gross margin61.68%
Net profit margin3.50%
Operating margin5.16%
Return on assets1.83%
Return on equity3.69%
Return on investment2.44%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Lumibird SA fell by 4.17m. Cash Flow from Financing totalled 21.69m or 10.66% of revenues. In addition the company generated 20.67m in cash from operations while cash used for investing totalled 46.15m.
Cash flow per share1.10
Price/Cash flow per share6.70
Book value per share8.62
Tangible book value per share2.77
More ▼

Balance sheet in EURView more

Lumibird SA has a Debt to Total Capital ratio of 42.87%, a higher figure than the previous year's 25.13%.
Current ratio2.66
Quick ratio1.62
Total debt/total equity0.7505
Total debt/total capital0.4287
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -36.72%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-8.94
EPS (TTM) vs
TTM 1 year ago		-25.24
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.